After a series of staff consolidation moves in recent weeks, Novartis is again trimming its ranks, albeit in what appears to ...

Valneva is planning to shrink its headcount by up to 15% as the French vaccine developer continues to seek ways to cut costs.

Three weeks after taking over as CEO of Lexicon Pharmaceuticals back in 2024, Michael Exton suggested the company close its ...

Aardvark Therapeutics is planning to unblind data from its phase 3 Prader-Willi syndrome (PWS) program after the FDA put a ...

Fosun Pharma has paid $60 million for an option on AriBio’s late-phase Alzheimer’s disease program, securing the chance to ...

Takeda has ended development of its nausea and vomiting drug candidate for strategic reasons, continuing its multi-year ...

As the wave of in vivo CAR-T hype crests, Create Medicines is catching the swell with a $122 million series B meant to back ...

Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the ...

Alumis is exploring strategic alternatives for its would-be rival to Amgen’s Tepezza, choosing to punt the program rather ...

Bristol Myers Squibb has formed a broad partnership with Hengrui Pharma, paying $600 million upfront to advance 13 early-stage programs from across the two companies’ pipelines. The deal could be ...

A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But while the ...

Immunogenicity dragged on the efficacy of AstraZeneca’s rare endocrine disorder prospect in a phase 3 trial, causing the $800 ...